2014

In just over a month, on September 30th, the Centers for Medicare and Medicaid Services (CMS) is scheduled to publish a searchable…

Recently, the US Food and Drug Administration (FDA) released a new draft guidance document on the content and format of…

As an update on our continuing coverage of the Open Payments website and physician dispute resolution process, the Centers for…

  August 14, 2014: The Centers for Medicare and Medicaid Services (CMS) have fixed the technical problems that caused Open…

We have written previously about the "Meaningful Use" electronic health record (EHR) initiative, which is run by the…

Since 2006, Celgene Corporation has earned $20.9 billion from the sales of two of its drugs—Thalomid and Revlimid. The drugs are…

Celgene's successful cancer drugs Thalomid and Revlimid are at the center of an antitrust action. On April 3rd, Mylan…

The European Medicines Agency (EMA) Management Board has been inching towards a policy on clinical trial transparency.…

A recent article in Forbes argues that misplaced public distrust of the pharmaceutical industry could harm the research and…

"There is a striking absence of transparency and accountability in the GME financing system for producing the types of physicians…